Table 4.
Ongoing clinical trials evaluating PARPi in combination with Immune checkpoint inhibitors in HER2 negative BC.
| Clinicaltrials.gov identifier | Phase | Treatment | Tumor type | Outcome measures |
|---|---|---|---|---|
| NCT03167619 | II | Olaparib + Durvalumab (anti-PD-L1) | Metastatic TNBC | PFS |
| NCT03544125 | I | Olaparib + Durvalumab | Metastatic TNBC | Proportion of completion of clinical laboratory improvement amendments analytics, Safety, ORR, CBR, DOR |
| NCT02484404 | I/II | Olaparib and/or Cediranib + Durvalumab (anti-PD-L1) | Advanced solid tumors and advanced or recurrent ovarian, TNBC, lung, prostate and colorectal cancers | Phase I: RP2D, safety Phase-II: ORR |
| NCT02734004 | I/II | Olaparib + Durvalumab (anti-PD-L1) | Advanced or metastatic solid tumors (ovarian, breast, SCLC, gastric cancer) | DCR, safety and tolerability |
| NCT02657889 | I/II | Niraparib + Pembrolizumab (anti-PD-1) | Advanced or metastatic TNBC or recurrent ovarian cancer | Phase I: RP2D, DLTs Phase-II: ORR |
| NCT02849496 | II | Veliparib + Atezolizumab (anti-PD-L1) | TNBC (stage III/IV) | PFS |